Connect with us

Media OutReach

Gynecomastia Affects All Ethnic Groups in Singapore, Amaris B. Clinic Study Reveals

Published

on

Amaris B. Clinic releases insights into gynecomastia cases, proving the condition affects men of all races in Singapore.

SINGAPORE – Media OutReach Newswire – 25 March 2025 – Gynecomastia, the development of excess male breast tissue disorder, is far more common than reported, yet it remains a misunderstood medical condition that is surrounded by stigma and misconceptions. One of the biggest myths in Singapore is that this enlarged male breast condition affects a particular racial group more than other ethnic groups.

Ethnicity of gynecomastia patients at Amaris B. Clinic from January 2018 to December 2024

Gynecomastia Transcends Beyond Ethnicity
Dr Ivan Puah, Medical Director of Amaris B. Clinic and an MOH-accredited liposuction doctor in Singapore, has spent nearly two decades successfully treating men struggling with gynecomastia, helping them regain confidence through his proprietary gynecomastia surgical approach – 360° GTD technique.

His recent study, analysing 602 patients treated for gynecomastia between January 2018 and December 2024, proved that gynecomastia affects men of all ethnicities in Singapore — debunking stereotypes that single out one racial group.

Dr Ivan Puah emphasised, “There is a common belief in Singapore that gynecomastia is more prevalent in certain ethnic groups, but my experience tells a different truth. I’ve treated patients from all racial backgrounds, proving that this condition isn’t selective — it can happen to any man, regardless of ethnicity.”

The Importance of Proper Diagnosis & Surgery

Not all gynecomastia cases are the same. Some men develop true gynecomastia, which involves excess glandular tissue, while others have mixed gynecomastia, a combination of glandular and fatty tissue. A proper medical diagnosis is crucial in determining the best treatment approach.

Dr Puah’s 360° Glandular Tissue Dissection (360° GTD) technique is less invasive. Unlike traditional gynecomastia surgeries, his technique effectively eliminates glandular tissue while achieving a more sculpted and masculine chest with minimal downtime and well-concealed scarring.

Gynecomastia in Singapore: The Reality Behind the Numbers
The study identified the patient demographics of individuals who sought gynecomastia surgery from Dr Ivan Puah:

  • 42.6% (263 patients) were Chinese
  • 19.7% (117 patients) were Indian
  • 12% (71 patients) were Caucasian
  • 8.9% (53 patients) were Malay

The rising number of Chinese patients seeking gynecomastia surgery at Amaris B. Clinic reflects a growing awareness, not higher susceptibility. Factors such as hormonal imbalances, genetics, obesity, underlying medical conditions, use of anabolic steroids and taking certain types of medications can lead to the development of male breast enlargement in Singapore, not ethnicity.

Why Many Men Suffer in Silence
Gynecomastia can have a devastating impact on self-esteem, causing not only physical discomfort such as pain and breast swelling but also crippling men’s confidence. Despite being common and treatable, many suffer in silence due to shame, misinformation, or fear of judgment.

“Our study proves no ethnicity is immune, and timely care is critical. Gynecomastia is not just a Singaporean issue, but it also transcends ethnicity, affecting men of all races and backgrounds globally. Too often, men think they have to just ‘live with it’ or that this medical condition is something they should be embarrassed about,” Dr Puah shares. “That couldn’t be further from the truth. Seeking expert help is the first step toward a better well-being and reclaiming your confidence.”

For those experiencing symptoms, an in-depth consultation with an experienced doctor in treating gynecomastia is essential for proper diagnosis and personalised treatment. With advancements in surgical techniques and a better understanding of the condition, no man should have to live with gynecomastia in silence.
Hashtag: #AmarisB.Clinic





The issuer is solely responsible for the content of this announcement.

About Amaris B. Clinic & Dr Ivan Puah

Established in 2004, Amaris B. Clinic is a medical aesthetics, sculpting and fitness clinic in Singapore. Led by Dr Ivan Puah, who is the clinic’s Medical Director and accredited by the Ministry of Health to perform liposuction, Amaris B.’s forte lies in body sculpting – surgically removing stubborn fat pockets to sculpt and shape different areas of the body through various services offered.

Chairman of the Lipo Peer Review Committee in Singapore, Dr Puah obtained his Vaser liposuction (fundamental and hi-definition) training in Colorado and Argentina. He has also received training in syringe liposculpture, fat grafting and thread lift by renowned French plastic surgeon, Dr Pierre Francois Fournier, and dedicated surgical training in gynecomastia surgery in San Francisco.

Dr Puah holds a Graduate Diploma in Family Dermatology from NUS, a Graduate Diploma in Acupuncture from TCMB, and a Graduate Diploma in Sports Medicine from LKCMedicine, NTU. He is the appointed trainer by Allergan and Merz for fellow doctors on cosmetic injectables such as neurotoxins and dermal fillers, as well as the designated trainer for PDO thread lift and Picolaser from Venusys Medical in Singapore.

Amaris B. Clinic’s signature treatments include:

Advertisement

Media OutReach

Asia Coach Group Partners with Veteran Business Consultant Rick Tam to Launch “Business Breakthrough” Programme for Hong Kong SMEs

Published

on

HONG KONG SAR – Media OutReach Newswire – 9 February 2026 – Asia Coach Group Limited announced today its partnership with seasoned business consultant Rick Tam to launch the “Business Breakthrough” enterprise training programme, designed to help Hong Kong SME owners strengthen their business models, improve cash flow, and enhance financing capabilities.

Rick Tam, Founder of “Business Breakthrough” Coaching Programme for Hong Kong SMEs

Challenging Business Environment Demands New Solutions

Hong Kong’s SMEs are facing unprecedented operational pressures. According to a survey by CPA Australia, 37% of small businesses in Hong Kong struggle to obtain external financing. Data from Airwallex further reveals that 96% of SMEs have experienced cash flow difficulties in the past year. With property asset values declining, banks’ insistence on property collateral for loans has left many enterprises in financial distress.

Responding to Market Needs with Systematic Business Upgrade Solutions

“Hong Kong has never lacked capital—what’s missing is the mechanism to connect businesses with it,” Rick Tam noted. The programme addresses common pain points faced by local SMEs, including declining profits, low business valuations, tight cash flow, and recruitment challenges. Built upon the four-pillar framework of “Commerce, Strategy, Breakthrough, and Structure,” the curriculum covers stabilising cash flow and enhancing financial flexibility, repositioning businesses and improving client quality, reshaping product value and expanding profit margins, as well as systematising operations and attracting investors. The programme commits to helping participants improve cash flow, increase business value, and strengthen their business models within 90 days.

Four Practical Tools for Immediate Application

Participants will acquire four core tools: the “Cash Flow Vortex System” for rapid assessment of financial status and establishing safety buffers; the “A.T.C. Client Leverage Ladder” for repositioning and enhancing client value; the “High-Value Breakthrough Method” for creating products with greater value and trust; and the “Marketing Triangle Matrix” for integrating human resources, client bases, and operational systems to plan business expansion. The programme adopts a six-step progressive model—from restructuring business models, improving profit margins, attracting capital injection, building high-performance teams, and systematising operations, to ultimately helping business owners reclaim their time and freedom.

Instructor Credentials

Programme instructor Rick Tam is a graduate of the University of Hong Kong’s Business School and currently serves as CEO of two family offices and chief consultant to several others. He holds the CFPCM Certified Financial Planner designation. Tam has founded more than nine brands spanning wealth management, securities, and food and beverage sectors, and has guided over 1,000 participants through business expansion.

As Hong Kong’s economy seeks transformation, channelling capital precisely into the real economy through the “Business Breakthrough” approach offers more than a lifeline for SMEs—it injects vital momentum into Hong Kong’s long-term economic development.

Hashtag: #RickTam #AsiaCoach

The issuer is solely responsible for the content of this announcement.

Continue Reading

Media OutReach

Zuellig Pharma Strengthens Consumer Healthcare Portfolio with the Acquisition of Zam-Buk® and Vapex® Brands from Bayer

Published

on

SINGAPORE – Media OutReach Newswire – 9 February 2026 – Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has acquired all rights, title, and interest in and to the Zam-Buk® and Vapex® consumer healthcare brands from Bayer Consumer Care AG for Thailand, Singapore, Indonesia, Malaysia and Brunei.

Zam-Buk® is an ointment used for the temporary relief of pain and itch, including discomfort from insect bites. First launched in 1902, Zam-Buk® has retained strong brand equity over the decades and is widely perceived as a trusted household brand. Vapex® is a nasal inhaler used to help relieve nasal congestion. Launched in 1917, Vapex® has built meaningful brand recognition, particularly in Thailand.

The acquisition of the brands supports Zuellig Pharma’s strategic priority to strengthen and scale its consumer healthcare portfolio across Asia. It also marks the company’s second consumer healthcare acquisition, following Propan in the Philippines, reinforcing its focus on building a strong commercial platform for trusted, everyday healthcare products in the region.

“This acquisition marks another significant growth milestone for our consumer healthcare product portfolio. Zam-Buk® and Vapex® are enduring brands with deep heritage and trust in the communities they serve. By combining the brands’ legacy with Zuellig Pharma’s regional commercial capabilities and local market expertise, we aim to expand distribution and access across all relevant retail channels in the region. In doing so, these brands will continue to remain relevant, easy to find, and accessible to consumers.” said John Graham, CEO of Zuellig Pharma.

Hashtag: #ZuelligPharma #ConsumerHealthcare #ConsumerHealth #Healthcare #Pharmaceuticals #Zambuk #Vapex #Bayer


The issuer is solely responsible for the content of this announcement.

About Zuellig Pharma

Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.

Continue Reading

Media OutReach

International Entertainment Corporation to Hold EGM on 26 February 2026 for Proposed Convertible Notes Issuance

Published

on

HONG KONG SAR – Media OutReach Newswire – 9 February 2026 – International Entertainment Corporation (the “Company“, together with its subsidiaries, the “Group“; HKEX stock code: 1009) will hold an extraordinary general meeting (the “EGM”) on 26 February 2026 at 11:00 a.m. for shareholders to vote on resolutions related to the proposed issuance of up to HK$1.6 billion convertible notes (the “Notes“) to DigiPlus Interactive Corp. (the “Subscriber“) (Philippine Stock Exchange stock symbol: PLUS).

DigiPlus Interactive Corp., named as one of the Fortune Southeast Asia 500, together with its subsidiaries, is an innovative digital entertainment group in the Philippines and is a leader in the casinos and gaming industry. On 17 November 2025, the Company entered into the Subscription Agreement with the Subscriber, pursuant to which the Company conditionally agreed to issue and the Subscriber conditionally agreed to subscribe for the Notes in two tranches with a maturity of five years and an interest rate of 3% per annum.

Upon full conversion of the Notes at the initial Conversion Price, a total of 1,600,000,000 Shares will be issued by the Company, representing approximately 53.89% of the issued share capital of the Company as enlarged by the issue and allotment of the Conversion Shares. As such, the Subscriber will be obliged to make a mandatory general offer pursuant to Rule 26.1 of the Takeovers Code, unless the Whitewash Waiver is granted and approved.

The initial Conversion Price of HK$1.00 per Conversion Share represents a discount of approximately 3.85% to the closing price of HK$1.04 per Share as quoted on the Stock Exchange on the Latest Practicable Date (6 February 2026).

The board of Directors (the “Board“) believes that the Subscription would be beneficial to improving and strengthening the Group’s liquidity and financial position on a longer-term basis. In the event that the Subscriber converts part or the full amount of the Notes into the Conversion Shares, it will also broaden the shareholder and capital base of the Company. The Group intends to apply part of the net proceeds raised from the issuance of the Notes of approximately HK$489.22 million for the early repayment of the Promissory Notes and interest accrued thereon (the “PN Repayment“), and approximately HK$392.39 million to early repay the Secured Bank Borrowing to achieve immediate interest savings.

The remaining net proceeds will primarily be used for funding the Investment Commitment and attractive investment/business opportunity(ies); and as general working capital of the Group. The Investment Commitment is currently expected to include capital investments for acquisition of land for the expansion of the Group’s integrated resort in Manila City in the Philippines (the ”Hotel”) and the construction of additional hotel rooms, for provision of other amenities of the integrated resort, and for ongoing upgrades, refurbishments and renovations to the facilities and infrastructures of both the Hotel and the Group’s existing casino (the “Casino“).

The Independent Board Committee, which comprises all the independent non-executive Directors, is of the opinion that (i) the terms of the Subscription Agreement are on normal commercial terms, and the terms of the Subscription, the Whitewash Waiver and the Special Deal (the PN Repayment to the PN Holder) are fair and reasonable so far as the Independent Shareholders are concerned; and (ii) the Subscription, the Whitewash Waiver and the Special Deal are in the interests of the Company and the Shareholders as a whole and as far as the Independent Shareholders are concerned. It, therefore, recommends the Independent Shareholders to vote in favour of the relevant resolution(s) to be proposed at the EGM.

Hashtag: #InternationalEntertainmentCorporation

The issuer is solely responsible for the content of this announcement.

About International Entertainment Corporation (HKEX: 1009)

International Entertainment Corporation is an investment holding company. The Company and its subsidiaries are principally involved in hotel operations, operating the gaming business under provisional licence and leasing of gaming venues at the hotel complex of the Group in Metro Manila in the Republic of the Philippines to a tenant for authorized gaming operation and live poker events in Macau.

Continue Reading

Trending